TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05284344
Drug: Anti-Diabetics
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: The anti-diabetic treatments include insulin glargine, insulin aspart, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, metformin, sulfonylureas and/or gliclazide. Therapeutic dose of each drug follows recommendation by the treating doctor.
Study: NCT06069804
Drug: The TR group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miscible liquid of triamcinolone acetonide and ropivacaine in this study will be peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, 0.25ml triamcinolone acetonide (40mg/ml), plus 10 ml saline miscible liquids for participants who will undergo elective craniotomy. Local infiltration of the study solution was performed by the neurosurgeon after induction of general anesthesia and intubation, once all equipment and catheters had been placed, during stable and steady state anesthetic conditions before skin incision. The solution was infiltrated with a 22-gauge needle introduced into the skin at a 45° angle throughout the entire thickness of the scalp along the planned incision site and the head-holder sites, by the same neurosurgeon. The total volume of the study solution used for each patient was determined by the neurosurgeon mainly based on the length of the incision and recorded by the investigator.
Study: NCT06069804
Drug: The R group
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, plus 10 ml saline miscible liquids for participants who will undergo elective craniotomy. Local infiltration of the study solution was performed by the neurosurgeon after induction of general anesthesia and intubation, once all equipment and catheters had been placed, during stable and steady state anesthetic conditions before skin incision. The solution was infiltrated with a 22-gauge needle introduced into the skin at a 45° angle throughout the entire thickness of the scalp along the planned incision site and the head-holder sites, by the same neurosurgeon. The total volume of the study solution used for each patient was determined by the neurosurgeon mainly based on the length of the incision and recorded by the investigator.
Study: NCT05405439
Drug: TQB3823 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3823 tablet is an inhibitor of poly ADP-ribose polymerase (PARP).
Study: NCT04984434
Drug: F182112
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eight dose cohorts: 0.01, 0.1, 0.3, 1, 3, 10, 20 and 30 μg/kg) d1 treat every weeks.
Study: NCT04789408
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT06444412
Drug: Ga 68 PSMA-11
Normalized name: Ga 68 PSMA-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast dye given IV
Study: NCT06399679
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral placebo by mouth once, followed by placebo by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
Study: NCT04871854
Drug: traditional Covid -19 therapy
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients treated with traditional therapy for Covid-19 infection
Study: NCT05444569
Drug: LY3537021
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05444569
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05353543
Drug: SSRIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this study, SSRIs antidepressants will be used, and the oral dose will be determined by the clinical specialist. Once-daily for 6 weeks.
Study: NCT06401707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05985863
Drug: standard medical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard medical treatment for ACLF
Study: NCT05985863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% human serum albumin in 0.9% saline (at week0, week1 and week2)
Study: NCT05641181
Drug: CRB4101
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the participants who signed the informed consent have been screened by the inclusion criteria, those who meet the inclusion criteria and those who do not meet the exclusion criteria will receive the following 6 dose groups in order from low to high:~100mg, 200 mg, 400 mg, 800 mg, 1200 mg, 1600 mg In each dose group, 8 participants will be enrolled to receive the drug, including 6 receiving CRB4101 tablets and 2 receiving placebo.
Study: NCT05641181
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the participants who signed the informed consent have been screened by the inclusion criteria, those who meet the inclusion criteria and those who do not meet the exclusion criteria will receive the following 6 dose groups in order from low to high:~100mg, 200 mg, 400 mg, 800 mg, 1200 mg, 1600 mg In each dose group, 8 participants will be enrolled to receive the drug, including 6 receiving CRB4101 tablets and 2 receiving placebo.
Study: NCT05564780
Drug: RASI and/or a single pill combination based RASI
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants in the Treatment group will begin with a single category antihypertensive drug to control their blood pressure, for example, perindopril. If the blood pressure cannot be controlled under 130/80 mmHg, another type of antihypertensive drug will be added.
Study: NCT06553365
Drug: FCN-159
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCN-159 8mg qd po
Study: NCT05469646
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT04721535
Drug: DWJ1248
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, 1 tablet of DWJ1248 TID, up to 14 days
Study: NCT04721535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, 1 tablet of placebo TID, up to 14 days
Study: NCT05062759
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection Q4W.
Study: NCT06448273
Drug: TQB3702 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3702 tablets is administered as a single dose on day 1, or once daily on Days 1 to 7 on multiple dose. Dosage: 100mg, 150/200mg.
Study: NCT06448273
Drug: TQB3702 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3702 placebo contains no active substance.
Study: NCT05151705
Drug: HR17031 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group B: HR17031 injection; 10U/0.024mg
Study: NCT05151705
Drug: HR17031 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group C: HR17031 injection; 10U/0.024mg
Study: NCT06293742
Drug: ECC5004
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECC5004 tablet will be administered orally.
Study: NCT06293742
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin will be administered orally.
Study: NCT05253495
Drug: DOC Group B
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 300 mg x1; dexamethasone x 7; vincristine x1
Study: NCT05253495
Drug: Pv-R-CYM 1 and 2 Group B
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: polatuzumab vedotin x 1; methotrexate x 1; rituximab x 1; cytarabine x 5;
Study: NCT05201092
Drug: [14C]-Lu AG06466
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]-Lu AG06466 will be administered per schedule specified in the arm description.
Study: NCT00000638
Drug: Pyridoxine hydrochloride
Normalized name: Pyridoxine Hydrochloride
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05253495
Drug: Bv-AVD-R 1 and 2: COHORT IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: brentuximab vedotin x 2; doxorubicin x 2; vinblastine x 2; dacarbazine 2x; rituximab x 2
Study: NCT05253495
Drug: Bv-NVD-R, Cycle 1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: brentuximab vedotin x 2; nivolumab x 2; vinblastine x2; dacarbazine x 2; rituximab x 2;
Study: NCT05253495
Drug: Bv-NVD-R, Cycle 1-4 SER
Approvals — FDA: no, EMA: no, PMDA: no
Description: brentuximab vedotin x 2; nivolumab x 2; vinblastine x 2; rituximab x 2;
Study: NCT05253495
Drug: Bv-AVD-R
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brentuximab vedotin x2; doxorubicin x2; vinblastine x 2; dacarbazine x 2; rituximab x2;
Study: NCT05253495
Drug: Bv-NVD-R, Cycle 1-4 RER
Approvals — FDA: no, EMA: no, PMDA: no
Description: brentuximab vedotin x 2; nivolumab x 2; vinblastine x 2; dacarbazine x 2; rituximab x 2;
Study: NCT05253495
Drug: Bv-NAVD-R, Cycle 1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: brentuximab vedotin x 2; nivolumab x 2; doxorubicin x 2; vinblastine x 2; dacarbazine x 2; rituximab x 2;
Study: NCT05918718
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methotrexate
Study: NCT04520490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly placebo injections
Study: NCT05638282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06279078
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral/inhaled corticosteroid
Study: NCT04582136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the double-blinded phase, placebo plus SOC is administered throughout 24 weeks; in the open-label extension period, patients who opt to participate are switched to receive sirolimus 1.5mg/day plus SOC for an additional 24 weeks.
Study: NCT05135169
Drug: Definity Suspension for Injection
Normalized name: Definity Suspension for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Definity
Study: NCT04753034
Drug: TER-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT04753034
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT06493838
Drug: intravenous 50 mL of saline injection of 0.9% after umbilical cord clamping.
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous 50 mL of saline injection of 0.9% after umbilical cord clamping.
Study: NCT06306339
Drug: SOC (Standard of care)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The following medications listed are allowed to be administered during the course of the clinical study.~1. biologic disease-modifying antirheumatic drug (bDMARD)~2. conventional synthetic disease-modifying antirheumatic drug (csDMARD)
Study: NCT06306339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo for Burfiralimab (hzVSF-v13)
Study: NCT05619328
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, with some liquid with or after a meal
Study: NCT06087770
Drug: SM3321
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion, once a week, 28 days for a dosing cycle
Study: NCT06383819
Drug: Longidaza®
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose 3000 IU intramuscularly once every 5 days, 15 injections
Study: NCT05620589
Drug: Amoxicillin + Tetracycline + Bismuth + Esomeprazole
Normalized name: bismuth biskalcitrate / metronidazole / tetracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Esomeprazole 40mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 40mg bid
Study: NCT06383819
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intramuscularly once every 5 days, 15 injections
Study: NCT05620589
Drug: Amoxicillin + Tetracycline + Bismuth + Vonoprazan
Normalized name: bismuth biskalcitrate / metronidazole / tetracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth +Vonoprazan 20mg bid or Amoxicillin1000mg bid+ Tetracycline 500mg tid+ Bismuth + Vonoprazan 20mg bid
Study: NCT05620589
Drug: Amoxicillin + Tetracycline + Bismuth + Tegoprazan
Normalized name: bismuth biskalcitrate / metronidazole / tetracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Tegopraza 50mg bid
Study: NCT05358691
Drug: AN0025
Approvals — FDA: no, EMA: no, PMDA: no
Description: To evaluate the safety and preliminary efficacy of AN0025 in combination with chemoradiation + consolidation durvalumab in Stage III Non-Small Cell Lung Cancer participants
Study: NCT04590118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of 1 ml/kg placebo
Study: NCT03567824
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will have the same appearance, taste, odor and mode of administration as MLD10.
Study: NCT06402019
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group went under multiple sessions of normal saline injection.
Study: NCT04849351
Drug: HMPL-689
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients are to receive monotherapy of HMPL-689 30 mg QD continuously in 28-day treatment cycles.
Study: NCT04530474
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive medication as a one time dose
Study: NCT05977036
Drug: CDK4/6 + Endocrine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDA-approved endocrine therapy plus CDK4/6 inhibitor. Ribociclib is the preferred CDK4/6 inhibitor. In the event this drug cannot be obtained due to insurance authorization or if there are specific side effect profile concerns from the treating physician, an alternative CDK4/6 inhibitor is allowed.
Study: NCT01028313
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg PO three times weekly
Study: NCT06226090
Drug: Placebo 7.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Dose is 7.5mg once a week.
Study: NCT06226090
Drug: Placebo 15 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.
Study: NCT06226090
Drug: TG103 22.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
Study: NCT06226090
Drug: Placebo 22.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
Study: NCT04958876
Drug: SP-104
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule once daily
Study: NCT05130047
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldafermin placebo solution
Study: NCT04852367
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin infusion
Study: NCT04852367
Drug: ThermoDox
Approvals — FDA: no, EMA: no, PMDA: no
Description: ThermoDox infusion
Study: NCT00561366
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo t.i.d.
Study: NCT06000137
Drug: Sufentanil injection
Normalized name: sufentanil Injection
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sufentanil for patient-controlled analgesia
Study: NCT06000137
Drug: Flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen for patient-controlled analgesia
Study: NCT02354612
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: companion therapy selection depends on companion therapy used in the parent study
Study: NCT04483466
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate is vibrant yellow-orange colored powder with physical properties of near insolubility in water formulated into methotrexate tablets containing an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate and are round, convex, and yellow. The chemical name is N-\[4-\[\[(2,4-diamino-6pteridinyl)methyl\]methyl amino\]benzoyl\]-L-glutamic acid. Methotrexate is an anti-metabolite that is a folate antagonist that inhibits lymphocyte proliferation and functions as an immunosuppressant in arthritis.
Study: NCT04483466
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05446233
Drug: [14C] Antaitavir Hasophate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg suspension containing 200µCi of \[14C\] Antaitavir Hasophate
Study: NCT04026880
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered by intramuscular injection weekly for 12 weeks
Study: NCT05189873
Drug: Long GnRH agonist + HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group:(Long GnRH agonist + HRT) From day 18-21 of the previous cycle, 0.5 cc of Superfect is injected daily and vaginal ultrasound is performed 10-14 days later If the endometrial thickness is less than 5 mm and there are no ovarian cysts, estradiol is started like HRT treatment and the agonist dose of GnRH starts with estradiol. It is halved (0.25 cc superfect) and superfect is prescribed until progesterone is started. At the time of progesterone administration, the administration of superfect is discontinued. Injections of estradiol and progesterone is the same as for the HRT group
Study: NCT05486416
Drug: HSK3486
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK3486 for induction of general anesthesia
Study: NCT03866499
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg gefitinib placebo tablet, QD
Study: NCT03866499
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg BPI-7711 placebo capsule, QD
Study: NCT05416073
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCIA formula：100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline.~30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min. After that, the intravenous analgesia pump was started. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h.~The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.
Study: NCT04452565
Drug: Drug: NA-831
Approvals — FDA: no, EMA: no, PMDA: no
Description: NA-831 is a neuroprotective drug, available at 30 mg capsule
Study: NCT05216497
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-2 capsules for 7 days on top of standard therapy
Study: NCT06349486
Drug: rabeprazole, amoxicillin, clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: proton pump inhibitor-based standard triple therapy
Study: NCT05303220
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified Dose on specified days
Study: NCT05303701
Drug: GV1001 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline
Study: NCT05303701
Drug: GV1001 1.12mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized peptide from hTERT
Study: NCT05852769
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05852769
Drug: Flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05852769
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05949073
Drug: impregnated gingival retraction cord - less than 10 minutes
Normalized name: EPINEPHRINE HCL 0.5MG RETRACTION CORD
Approvals — FDA: no, EMA: no, PMDA: no
Description: lower first molar will be prepared for full coverage restoration, Aluminum chloride-impregnated retraction cord will be placed in the sulcus just before impression recording (less than 10 minutes).
Study: NCT06196632
Drug: Peginterferon-α; Nucleoside analogs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with chronic hepatitis B were treated with the combination of peginterferon-α and nucleoside analogs
Study: NCT04825561
Drug: AD-208
Normalized name: testosterone 0.208 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 24weeks
Study: NCT04825561
Drug: placebo of AD-208
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 24weeks
Study: NCT04825561
Drug: placebo of AD-2081
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 24weeks
Study: NCT04702360
Drug: ELX/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablet for oral administration.
Study: NCT05571345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match PF614 capsules will be provided by the sponsor.
Study: NCT05553405
Drug: Intralipid Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid 20% (a 20% IV fat emulsion) is a sterile, non-pyrogenic fat emulsion prepared for IV administration as a source of calories and essential fatty acids. It is made up of 20% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin and water for injection. In addition, sodium hydroxide has been added to adjust the pH so that the final product pH is 8.
Study: NCT06606483
Drug: MDR-001
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of small molecule MDR-001 tablets
Study: NCT06606483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally placebo
Study: NCT04531865
Drug: Placebo tablets matching Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Addition of Maintenance Placebo tablets matching Mycophenolate Mofetil from 4 Month onwards. Dose: 20\~30mg/kg/day，BID. Total duration : 8 months.
Study: NCT04830735
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO